TAVALISSE®, GAVRETO®, & REZLIDHIA®
January 7, 2026
FOR IMMEDIATE RELEASE:
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
Louisville, KY — January 7, 2026 — Onco360®, the nation’s leading independent specialty pharmacy, has been chosen by Rigel Pharmaceuticals as a limited distribution specialty pharmacy partner for TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib), and REZLIDHIA® (olutasidenib).
“We are looking forward to serving as one of Rigel Pharmaceuticals’ national specialty pharmacy providers and expanding our portfolio of limited distribution therapies,” said Benito Fernandez, Chief Commercial Officer. “Our strategic imperative is to deliver the highest level of personalized service, clinical expertise, and compassionate support to patients and their caregivers.”
With a focus on oncology, rare, and complex disease, Onco360 combines national reach with clinical innovation, and a commitment to improving access and adherence with our relentless commitment to quality and service.
Media Contact: Benito Fernandez, Chief Commercial Officer
516-640-1332